Business Development Manager
Todd Giardiello holds a Bachelor of Science in Microbiology from Kutztown University and has been a part of the Rockland team since 2008. Over the years, he has progressed through several key positions throughout the lab and project management, now excelling as a Business Development Manager for Rockland's Complex Therapy Solutions line of business. Todd combines a strong scientific background with strategic insights to support our partners. Beyond his professional pursuits, Todd enjoys playing sports and building with Lego.
Articles
-
Evaluation of Novel High-Coverage Generic CHO-HCP Reagents
Here we evaluate and demonstrate improved coverage of a new generic CHO-HCP reagent developed at Rockland. -
Localization and Quantification of Oligonucleotide Therapeutic Drugs
This poster presents the development of universal detection reagents specific for nucleic acid modifications. -
Lyme Disease: The Situation & Solution
Our solution engages the evasive nature of B. burgdorferi and the different bacterial phases and allows for the detection of the unique response of each patient. -
New Tools to Quantify and Localize ASOs and siRNAs
This white paper introduces ModDetect™ antibody panels, new tools for detecting and localizing modified antisense oligonucleotides (ASOs) and siRNAs. Traditional methods like qPCR fall short with modified ONTs, while ModDetect™ provides a sensitive, versatile solution for assays such as ELISA and immunofluorescence, supporting ONT biodistribution and therapeutic studies. -
Robust Methods for Anti-Oligonucleotide Antibody Generation
In this poster we summarize our expertise in developing oligo-specific antibody reagents to a number of different target chemistries. -
The Utility of Antibodies When Investigating SARS-CoV-2 & Variants of Concern
This white paper discusses the drawbacks of monoclonal antibodies and the benefits of polyclonal antibodies in infectious disease detection. Plus, we show the detection of the Omicron variant by immunofluorescence microscopy within infected A549 cells using Rockland's polyclonal anti-Nucleocapsid antibody.